MedPath

Regadenoson

Generic Name
Regadenoson
Brand Names
Lexiscan, Rapiscan
Drug Type
Small Molecule
Chemical Formula
C15H18N8O5
CAS Number
313348-27-5
Unique Ingredient Identifier
7AXV542LZ4
Background

Regadenoson is an A2A adenosine receptor agonist that causes coronary vasodilation and used for myocardial perfusion imagining. Manufactured by Astellas and FDA approved April 10, 2008.

Indication

Diagnostic agent for radionuclide myocardial perfusion imaging (MPI)

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

Use of Lexiscan for Myocardial Stress Perfusion Computed Tomography With a 3rd Generation Dual Source CT System

Phase 2
Completed
Conditions
Cardiovascular Diseases
Coronary Artery Disease
Interventions
Drug: Lexiscan
First Posted Date
2017-04-06
Last Posted Date
2019-08-09
Lead Sponsor
Medical University of South Carolina
Target Recruit Count
24
Registration Number
NCT03103061
Locations
🇺🇸

Medical University of South Carolina, Charleston, South Carolina, United States

Allograft Dysfunction in Heart Transplant

Phase 4
Recruiting
Conditions
Heart Transplant Failure and Rejection
Interventions
Drug: Regadenoson
First Posted Date
2017-04-05
Last Posted Date
2024-05-08
Lead Sponsor
Paul Kim
Target Recruit Count
376
Registration Number
NCT03102125
Locations
🇺🇸

UC San Diego, La Jolla, California, United States

The Effect of A2A Adrenoceptor Stimulation on the Diameter of Retinal Arterioles During Hypoxia in Vivo

Phase 2
Conditions
Retinal Artery Occlusion
Interventions
Biological: Hypoxia
Drug: Regadenoson
First Posted Date
2017-03-24
Last Posted Date
2017-03-28
Lead Sponsor
University of Aarhus
Target Recruit Count
20
Registration Number
NCT03090087
Locations
🇩🇰

Department of Ophthalmology, Aarhus University Hospital, Aarhus, Denmark

Assessment of Global Myocardial Perfusion Reserve Using Coronary Sinus Flow Measurements

Completed
Conditions
Coronary Artery Disease
Interventions
Drug: Regadenoson
First Posted Date
2016-03-03
Last Posted Date
2019-10-24
Lead Sponsor
University of Illinois at Chicago
Target Recruit Count
183
Registration Number
NCT02697877
Locations
🇺🇸

1740 W Taylor Street, 2nd Floor, Cardiac Imaging, Chicago, Illinois, United States

Comparison of Quantitative MRI Perfusion Methods With Quantitative PET Perfusion Imaging

Not Applicable
Withdrawn
Conditions
MRI Scans
Interventions
Drug: Adenosine
Drug: Regadenoson
Drug: O-15 labeled radioactive water
Device: MRI
Device: PET Imaging
First Posted Date
2015-11-20
Last Posted Date
2020-09-14
Lead Sponsor
University of Utah
Registration Number
NCT02608944
Locations
🇺🇸

University of Utah, Radiology Research, Salt Lake City, Utah, United States

Stress Cardiac MRI for Evaluation of Nonspecific Allograft Dysfunction

Phase 4
Completed
Conditions
Chronic Graft Rejection
Acute Graft Rejection
Heart Transplant
Interventions
Drug: Regadenoson
Drug: Gadolinium
Procedure: Cardiac MRI
First Posted Date
2015-11-05
Last Posted Date
2017-08-22
Lead Sponsor
Paul Kim
Target Recruit Count
14
Registration Number
NCT02597543
Locations
🇺🇸

UC San Diego, La Jolla, California, United States

Myocardial Perfusion, Oxidative Metabolism, and Fibrosis in HFpEF

Phase 4
Completed
Conditions
Heart Failure, Diastolic
Diastolic Heart Failure
Hypertension
Interventions
Drug: regadenoson
First Posted Date
2015-10-28
Last Posted Date
2021-02-02
Lead Sponsor
Marvin W. Kronenberg, M.D.
Target Recruit Count
55
Registration Number
NCT02589977
Locations
🇺🇸

Vanderbilt University Medical Center, Nashville, Tennessee, United States

Brain Interstitium Temozolomide Concentration Pre and Post Regadenoson Administration

Early Phase 1
Completed
Conditions
Blood Brain Barrier Defect
Interventions
Drug: Regadenoson
Drug: Temozolomide
Device: Microdialysis catheter
First Posted Date
2015-03-17
Last Posted Date
2018-11-20
Lead Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Target Recruit Count
6
Registration Number
NCT02389738
Locations
🇺🇸

Johns Hopkins Hospital, Baltimore, Maryland, United States

Regadenoson for Acute Vasoreactivity Testing in Pulmonary Hypertension

Not Applicable
Terminated
Conditions
Pulmonary Hypertension
Interventions
Drug: Regadenoson
First Posted Date
2014-08-20
Last Posted Date
2021-01-19
Lead Sponsor
National Jewish Health
Target Recruit Count
10
Registration Number
NCT02220634
Locations
🇺🇸

National Jewish Health, Denver, Colorado, United States

Accuracy of an Echo-Stress Protocol Using Regadenoson With Speckle Tracking

Phase 4
Completed
Conditions
Ischemia
Interventions
Drug: Regadenoson
First Posted Date
2014-05-05
Last Posted Date
2024-10-02
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
161
Registration Number
NCT02130453
Locations
🇺🇸

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy